Maravai LifeSciences (MRVI) Revenue & Revenue Breakdown
Maravai LifeSciences Revenue Highlights
Latest Revenue (Y)
$259.19M
Latest Revenue (Q)
$65.20M
Main Segment (Y)
Nucleic Acid Production Segment
Main Geography (Y)
North America
Maravai LifeSciences Revenue by Period
Maravai LifeSciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $259.19M | -10.30% |
| 2023-12-31 | $288.94M | -67.28% |
| 2022-12-31 | $883.00M | 10.48% |
| 2021-12-31 | $799.24M | 181.33% |
| 2020-12-31 | $284.10M | 98.48% |
| 2019-12-31 | $143.14M | 15.59% |
| 2018-12-31 | $123.83M | - |
Maravai LifeSciences generated $259.19M in revenue during NA 2024, up -10.30% compared to the previous quarter, and up 181.07% compared to the same period a year ago.
Maravai LifeSciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $65.20M | -11.17% |
| 2024-06-30 | $73.40M | 14.37% |
| 2024-03-31 | $64.18M | -13.44% |
| 2023-12-31 | $74.14M | 10.88% |
| 2023-09-30 | $66.86M | -2.97% |
| 2023-06-30 | $68.91M | -12.79% |
| 2023-03-31 | $79.03M | -61.40% |
| 2022-12-31 | $204.71M | 7.03% |
| 2022-09-30 | $191.26M | -21.20% |
| 2022-06-30 | $242.73M | -0.64% |
| 2022-03-31 | $244.29M | 6.94% |
| 2021-12-31 | $228.44M | 11.54% |
| 2021-09-30 | $204.81M | -5.95% |
| 2021-06-30 | $217.78M | 46.94% |
| 2021-03-31 | $148.21M | 50.69% |
| 2020-12-31 | $98.35M | 11.94% |
| 2020-09-30 | $87.86M | 87.31% |
| 2020-06-30 | $46.91M | -8.00% |
| 2020-03-31 | $50.98M | 41.77% |
| 2019-12-31 | $35.96M | - |
Maravai LifeSciences generated $65.20M in revenue during Q3 2024, up -11.17% compared to the previous quarter, and up 94.61% compared to the same period a year ago.
Maravai LifeSciences Revenue Breakdown
Maravai LifeSciences Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|
| Biologics Safety Testing Segment | $62.84M | $64.18M | - | - |
| Nucleic Acid Production Segment | $196.34M | $224.77M | - | - |
| Protein Detection Segment | - | - | - | - |
| Shipping and Handling | - | - | $3.20M | $3.60M |
Maravai LifeSciences's latest annual revenue breakdown by segment (product or service), as of Dec 24: Nucleic Acid Production Segment (75.75%), and Biologics Safety Testing Segment (24.25%).
Quarterly Revenue by Product
| Product/Service | Dec 24 | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nucleic Acid Production Segment | $100.38M | $49.95M | $46.02M | $58.83M | $51.23M | $53.27M | $61.45M | $189.29M | $174.88M | $225.25M | $223.65M | $212.51M | $182.90M | $192.52M | $123.93M |
| Biologics Safety Testing Segment | $29.42M | $15.25M | $18.16M | $15.32M | $15.64M | $15.65M | $17.57M | $15.42M | $16.38M | $17.48M | $20.64M | $15.93M | $16.63M | $18.21M | $17.65M |
| Protein Detection Segment | - | - | - | - | - | - | - | - | - | - | - | $5.28M | $7.05M | $6.63M | - |
Maravai LifeSciences's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Nucleic Acid Production Segment (77.33%), and Biologics Safety Testing Segment (22.67%).
Maravai LifeSciences Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 24 | Dec 23 |
|---|---|---|
| Latin And Central America | $662.00K | $527.00K |
| North America | $127.09M | $141.06M |
| Asia Pacific | $89.38M | $97.44M |
| EMEA | $42.05M | $49.92M |
Maravai LifeSciences's latest annual revenue breakdown by geography, as of Dec 24: North America (49.03%), Asia Pacific (34.48%), EMEA (16.23%), and Latin And Central America (0.26%).
Quarterly Revenue by Country
| Country | Dec 24 | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Mar 21 |
|---|---|---|---|---|---|---|
| Asia Pacific | $45.32M | $22.92M | $21.14M | $72.82M | $24.62M | $15.98M |
| EMEA | $25.23M | $7.46M | $9.37M | $42.30M | $7.62M | $53.72M |
| Latin And Central America | $230.00K | $125.00K | $307.00K | $422.00K | $105.00K | $220.00K |
| North America | $59.03M | $34.69M | $33.37M | $106.54M | $34.52M | $78.30M |
Maravai LifeSciences's latest quarterly revenue breakdown by geography, as of Dec 24: North America (45.47%), Asia Pacific (34.92%), EMEA (19.43%), and Latin And Central America (0.18%).
Maravai LifeSciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| INCY | Incyte | $4.24B | $962.99M |
| ARGX | argenx SE | $1.23B | $401.00M |
| HALO | Halozyme Therapeutics | $1.02B | $290.08M |
| HRMY | Harmony Biosciences | $714.73M | $186.04M |
| APLS | Apellis Pharmaceuticals | $709.95M | $176.57M |
| RARE | Ultragenyx Pharmaceutical | $560.23M | $147.03M |
| FOLD | Amicus Therapeutics | $528.29M | $141.52M |
| INSM | Insmed | $363.71M | $93.42M |
| KRYS | Krystal Biotech | $290.51M | $83.84M |
| LEGN | Legend Biotech | $285.14M | $93.99M |
| ASND | Ascendis Pharma | $266.72M | $95.89M |
| MRVI | Maravai LifeSciences | $259.19M | $65.20M |
| ARQT | Arcutis Biotherapeutics | $196.54M | $30.86M |
| ROIV | Roivant Sciences | $124.80M | $9.02M |
| ALEC | Alector | $100.56M | $15.08M |
| AGIO | Agios Pharmaceuticals | $36.50M | $8.96M |
| CYTK | Cytokinetics | $18.47M | $463.00K |
| ABUS | Arbutus Biopharma | $6.17M | $1.73M |
| AKRO | Akero Therapeutics | - | - |
| PTGX | Protagonist Therapeutics | - | $4.67M |
| EWTX | Edgewise Therapeutics | - | - |
| IMVT | Immunovant | - | - |
| DNLI | Denali Therapeutics | - | - |